clinical trial · NCT05505916
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Hereditary AngioedemaKVD900 600 mgKVD900 300 mg
brief summary
This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.
started
Oct 24, 2022
primary completion
Jun 30, 2026
completion
Jun 30, 2026
last updated
Feb 18, 2026
official title
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol